	US 11,987,600 B2
	Contraceptive use of triterpenoids
Polina V. Lishko, Berkeley, CA (US); and Nadja Mannowetz, Berkeley, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jun. 18, 2019, as Appl. No. 16/444,992.
Application 16/444,992 is a continuation of application No. PCT/US2018/012015, filed on Jan. 2, 2018.
Claims priority of provisional application 62/442,964, filed on Jan. 5, 2017.
Prior Publication US 2019/0300565 A1, Oct. 3, 2019
Int. Cl. A61K 31/56 (2006.01); A61K 9/00 (2006.01); A61P 15/00 (2006.01); A61P 15/18 (2006.01); C07J 53/00 (2006.01)

CPC C07J 53/002 (2013.01) [A61K 9/00 (2013.01); A61K 9/0034 (2013.01); A61K 9/0036 (2013.01); A61K 31/56 (2013.01); A61P 15/00 (2018.01); A61P 15/18 (2018.01)]

4 Claims

1. A pharmaceutical composition comprising a polymeric intrauterine device (IUD) impregnated with a spermicidal triterpenoid in a predetermined dosage effective for human contraception, wherein the triterpenoid is selected from the group consisting of pristimerin, celastrol and lupeol.